Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and sof-tissue infections

Annals of Pharmacotherapy

Volumn 40, Issue 6, 2006, Pages 1017-1023

  McKinnon, Peggy S ^a   Sorensen, Sonja V ^b   Liu, Larry Z ^c   Itani, Kamal M F ^d,e  

^a BARNES JEWISH HOSPITAL   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c PFIZER INC   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BOSTON MEDICAL CENTER   (United States)

Author keywords

Linezolid; Methicillin resistant Staphylococcus aureus; Pharmacoeconomics; Skin and soft tissue infection; Vancomycin

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHARMACOECONOMICS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; UNITED STATES;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZTREONAM; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; OXAZOLIDINONES; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SKIN DISEASES, INFECTIOUS; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 33745088289     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G728     Document Type: Article

References (28)

1. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004;64:1621-42.
2. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003;52(suppl 1):i3-17.
3. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001;33(suppl 2):S84-93.
4. Wilson SE. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections. Surg Infect (Larchmt) 2001;2:25-35.
5. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S114-32.
6. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002;23:106-8.
7. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999;20:408-11.
8. Carbon C. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. J Antimicrob Chemother 1999;44(suppl A):31-6.
9. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
10. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999;5:9-17.
11. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-8.
12. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6.
13. Hau T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur J Clin Microbiol Infect Dis 2002;21:491-8.
14. Itani KMF, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005;26:442-8.
15. Red book. 2004 ed. Montvale, NJ: Thomson physicians' desk reference, 2004.
16. Premier Perspective Hospital Claims [database]. Washington, DC: Premier, Inc., 2004 (created 2004 Apr 6).
17. Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001;21:263-74.
18. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90.
19. Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005;189:425-8.
20. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760-6.
21. Greene WH. Econometric analysis. 4th ed. Englewood Cliffs, NJ: Prentice-Hall, Inc., 1999.
22. McCollum M, Rhew DC, Parodi S. Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species. Clin Ther 2003;25:3173-89.
23. Parodi S, Rhew DC, Goetz MB. Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections. J Manag Care Pharm 2003;9:317-26.
24. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) 2003;4:57-70.
25. Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch Intern Med 2000;160:1237-8.
26. Pujol M, Pena C, Pallares R, Ayats J, Ariza J, Gudiol E. Risk factors for nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1994;13:96-102.
27. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406.
28. Lodise TP Jr, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol 2003;24:655-61.